Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.
about
The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening ProgramsCalibration methods used in cancer simulation models and suggested reporting guidelinesType-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women.Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in KenyaModeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India.An updated natural history model of cervical cancer: derivation of model parameters.Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policiesCost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparitiesEvolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians.Quantifying demographic and socioeconomic transitions for computational epidemiology: an open-source modeling approach applied to India.Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.Anal cancer and human papillomaviruses in heterosexual men.Modeling cervical cancer prevention in developed countries.Trade-offs in cervical cancer prevention: balancing benefits and risks.Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.The cost effectiveness of human papillomavirus vaccines: a systematic review.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses.The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania.Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis.How various design decisions on matching individuals in relationships affect the outcomes of microsimulations of sexually transmitted infection epidemics
P2860
Q26851181-6FC77CC5-F546-4ABA-9D5B-B5FB1898CD99Q28749665-54F96219-FE29-41AD-BE23-FA084C5AD3A2Q30712681-9A4D4BFB-4E8B-49B4-870E-FA93C7486F25Q33724701-03D0938C-0DEA-4FD9-AC2F-C16DD175E209Q33909353-08A49A05-D86D-4247-970B-3B197D708304Q33969384-B70303AE-3F16-4377-A66D-E42BEF3F4E80Q34083083-61EFD1FA-BD1C-4E9F-BC14-53F8B1DEF754Q34199773-27371D37-87F3-46D9-B5C6-F08700FC364CQ34461262-939F89F8-E2B2-4C27-950B-84B63DE7A6C2Q34997604-CBF4A6F5-04EC-441D-B771-234FEFC7192BQ35127307-CA49C4C4-AC17-4422-85E7-B62278E8E7A5Q35223397-8BE9B075-2FFC-4B07-A7BA-E35A591C2398Q35889801-EB59344F-714B-4120-8A39-152E6699F41DQ35906207-60F2139F-B1E5-41F1-A90A-6A1E50040D98Q35927132-0D59DEA6-324E-470F-8CD5-E90CD0255668Q36785915-DF4BDE65-CBEB-4EC8-B869-5B5D892B9A4EQ36971738-97B60015-8AEA-41C5-B4E8-DEDF3D767BE2Q37291448-3B0FFBAE-E16E-4DED-87B3-BBDD8D5FC823Q37352821-A75A5489-834A-4365-8EA4-7A32ECDF3B0DQ37425356-1FA3D5CF-C082-490E-A038-A1D835FBC525Q37993109-C0E860D3-6B19-48B2-A776-662FF998381FQ38549643-69C23FA4-5B3A-4021-B4B1-2C7199F0354EQ38850707-C0F6B726-91D2-402D-BB2C-4FE1980A823AQ38851920-EB8FE908-CFC4-4FC8-B611-1C6817B9F87AQ39553755-7D048EBE-F3E4-411C-91DB-F92643E1B8CEQ39553769-175E74BE-4CA4-4825-9780-1E22D516478CQ39825094-878A375F-9AEB-41A0-95B6-77B0A694C5D3Q40025709-FAF8F725-1C23-42DB-B39A-C9E8536C657FQ41350473-2BA4B99B-8E01-4451-B288-F89A38569E6FQ41499207-938BDD95-683E-453C-8961-7FA02E787100Q42589331-1072FD26-AC43-41AF-87FF-FEEFF4EDF6E6Q45049771-8023D620-EF32-4571-8831-E5F7B37CF183Q45074054-786FA8CF-F5DE-4AA6-B101-4BB4FB090A1BQ46659871-E6CEFBCB-B5B9-412B-9438-8E502E2B1443Q51148505-48FF03A9-C284-4211-B786-ABB0BA245342Q51434170-2747C933-DBA7-42C5-AAD4-6F4CADA4F0B0Q53290879-2226CC3B-B02C-4950-9DBB-B9812C62A8D5Q54962711-F95357E7-A9FC-4071-A52E-9DC3B466A437Q58696169-03665D50-BCF1-41B6-9AD8-21C550774699
P2860
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Modeling human papillomavirus ...... of screening and vaccination.
@ast
Modeling human papillomavirus ...... of screening and vaccination.
@en
type
label
Modeling human papillomavirus ...... of screening and vaccination.
@ast
Modeling human papillomavirus ...... of screening and vaccination.
@en
prefLabel
Modeling human papillomavirus ...... of screening and vaccination.
@ast
Modeling human papillomavirus ...... of screening and vaccination.
@en
P2093
P2860
P356
P1476
Modeling human papillomavirus ...... of screening and vaccination.
@en
P2093
Jesse Ortendahl
Joshua A Salomon
Karen M Kuntz
Natasha K Stout
P2860
P2888
P356
10.1186/1478-7954-5-11
P577
2007-10-29T00:00:00Z
P5875
P6179
1051176999